VEGFA and age-related macular degeneration: Best BCVA improved significantly to 1.0 (range 0.2–2.7) in AMD (P < 0.0001), 0.95 (range 0.0–2.6) in DME (P = 0.019), and 1.0 (range 0.1–2.3) in RVO (P < 0.0001) within the first 6 months after initiating VEGF-inhibitor therapy.